Recent clinical trials showed transient hypoglycemia in patients with Pompe disease shortly after intravenous injection of recombinant IGF2.GAA at 10–20 mg/kg, but not at 5 mg/kg.73 This evidence concerns the gene IGF2 and Glycogen storage disease due to acid maltase deficiency.